Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

PF-04991532

SKU: orb1706822

Description

PF-04991532 is a hepatoselective glucokinase activator with EC50 values of 80 nM (human) and 100 nM (rat). It has demonstrated efficacy in reducing plasma glucose and AMP levels in the diabetic Goto-Kakizaki rat model, supporting its use in diabetes and metabolic disorder research.

Research Area

Metabolism Research

Images & Validation

Key Properties

CAS Number1215197-37-7
MW396.36
Purity99.99% (May vary between batches)
FormulaC18H19F3N4O3
SMILES[C@H](CC1CCCC1)(C(NC2=CC=C(C(O)=O)C=N2)=O)N3C=C(C(F)(F)F)N=C3
TargetGlucokinase
SolubilityDMSO:100 mg/mL (252.3 mM);10% DMSO+40% PEG300+5% Tween-80+45% Saline:3.3 mg/mL (8.33 mM)

Bioactivity

Target IC50
glucokinase (rat):100 nM(EC50)|glucokinase (human):80 nM(EC50)
In Vivo
PF-04991532 (a single dose) enhances the glucose infusion rate in order to maintain hyperglycemia. PF-04991532 (in rats) treatment, there is increased expression of lipogenic gene expression such as acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), and fatty acid synthase (FAS). Despite the elevations in plasma triglycerides, hepatic triglycerides in rats dosed with 19 days of PF-04991532 are identical to vehicle-treated GK rats. Identical hepatic lipid concentrations are observed between vehicle and rats dosed with PF-04991532 (Vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31), in an additional cohort treated for 28 days .
In Vitro
PF-04991532 is a Phase 2 clinical candidate. PF-04991532 reduces the production of glucose from 1-[14C]-lactate in a dose-dependent manner (EC50=0.626 μM). PF-04991532 enhances the expression of G6Pase compare to cells treated only with 100 nM glucagon, in isolated rat hepatocytes. The greatest increase in G6Pase mRNA expression is in the presence of 25 mM glucose, 100 nM glucagon, and PF-04991532. Mechanistic experiments conducted in freshly isolated primary rat hepatocytes treated for 1 hour with PF-04991532 display increased 2-[14C]-deoxyglucose uptake (EC50=1.261 μM) and increased glucose oxidation (EC50=5.769 μM) .

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

glucokinase, glucokinase in human, PF04991532, PF-04991532, PF 04991532

Similar Products

  • (R)-PF-04991532 [orb1744697]

    396.36

    C18H19F3N4O3

    50 mg, 25 mg, 100 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 90.00
2 mg
$ 100.00
5 mg
$ 140.00
1 ml x 10 mM (in DMSO)
$ 150.00
10 mg
$ 210.00
25 mg
$ 320.00
50 mg
$ 460.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry